Concert Pharmaceuticals to conduct public offering of common stock

Wells Fargo Securities and JMP Securities will be bookrunners for deal

By Devika Patel

Knoxville, Tenn., March 18 – Concert Pharmaceuticals Inc. will price a public offering of common stock with a 30-day, 15% greenshoe, according to a preliminary prospectus supplement filed Wednesday with the Securities and Exchange Commission.

Wells Fargo Securities, LLC and JMP Securities LLC are the bookrunners.

Proceeds will be used for clinical development, research and preclinical development, working capital and other general corporate purposes.

Concert is a clinical-stage biopharmaceutical company based in Lexington, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.